Two-thirds of this high-risk group were not reaching the treatment outcome
Ethiopia has built one of Africa's most ambitious HIV treatment infrastructures, yet a new study from Northwest Ethiopia reveals that two-thirds of adults living with both HIV and hepatitis B are failing to achieve viral suppression — the clinical threshold that separates stability from ongoing harm. The finding is not a failure of medicine but of integration: drugs exist, clinics exist, yet the layered burdens of co-infection, poverty, stigma, and system design are quietly undoing the progress. It is a reminder that access to treatment and access to healing are not the same thing, and that the patients most in need are often the ones systems are least equipped to hold.
- Only one in three co-infected patients in a four-hospital study achieved viral suppression, leaving 264 people at elevated risk of liver disease, immune collapse, and onward transmission.
- Hepatitis B co-infection raises the stakes of every missed dose — it can accelerate cirrhosis and liver cancer, turning a manageable chronic condition into a compounding medical crisis.
- Adherence emerged as the strongest predictor of suppression, but it is being eroded by transport costs, food insecurity, stigma, and clinic models that assume patients can show up reliably.
- Bedridden patients were far less likely to achieve suppression, exposing a structural blind spot: care systems built around clinic visits cannot reach those too ill to travel.
- Ethiopia's path forward requires integrated HIV-HBV screening, liver monitoring, differentiated care models, and appointment-tracking systems — moving from treatment availability to treatment continuity.
Ethiopia has spent years building one of Africa's most ambitious HIV treatment programs — expanding clinics, increasing drug access, and pushing toward global targets. But a new study from Northwest Ethiopia has found a quiet failure within that progress: patients living with both HIV and hepatitis B are not being adequately served.
Researchers studied 402 adults with HIV-hepatitis B co-infection across four referral hospitals. Only 138 — roughly one-third — achieved HIV viral suppression, the clinical marker that signals the virus is controlled and transmission risk is sharply reduced. The remaining two-thirds remained unsuppressed, a troubling outcome for a group already facing compounded medical risk. Hepatitis B accelerates liver disease, raises the likelihood of cirrhosis and liver cancer, and makes treatment far more complex than HIV alone.
Adherence to medication was the strongest predictor of suppression — but the study makes clear that adherence is not simply a matter of personal discipline. Transport costs, stigma, food insecurity, side effects, and long clinic waiting times all erode a patient's ability to stay consistent. For co-infected patients, the consequences of missed doses are steeper: not just HIV treatment failure, but potential acceleration of liver damage. Yet adherence support in most settings remains generic counselling rather than the intensive, individualized intervention these patients require.
Missed clinic appointments compounded the problem. Bedridden patients were far less likely to achieve suppression than those who could work and travel — a signal that standard clinic-based care models are failing those with the most advanced disease. The study also found that specific regimen choices and longer time on antiretroviral therapy were associated with better outcomes, pointing to the importance of sustained, informed treatment engagement.
The research has limitations — it was cross-sectional, adherence was self-reported, and the absence of HBV-DNA data constrained the full picture. But its message to policymakers is clear: Ethiopia needs integrated co-infection screening, stronger liver and viral load monitoring, differentiated care for high-risk patients, and community-based retention models. The broader lesson reaches beyond Ethiopia — the next phase of HIV progress across the Global South will not be won by making treatment available. It will be won by building systems capable of continuously caring for the patients who are hardest to reach and easiest to leave behind.
Ethiopia has spent years building one of Africa's most ambitious HIV treatment programs. Antiretroviral drugs are reaching people. Clinics are opening. Testing is expanding. By most measures, the country is on track with global targets. But a new study from Northwest Ethiopia has found a stubborn crack in that progress: patients living with both HIV and hepatitis B are slipping through.
Researchers working across four referral hospitals studied 402 adults with HIV-hepatitis B co-infection. The numbers tell a stark story. Only 138 of them—roughly one-third—achieved HIV viral suppression, the clinical marker that means the virus is controlled, the immune system can recover, and transmission risk drops sharply. The other 264 patients remained unsuppressed. Two-thirds of this high-risk group were not reaching the treatment outcome that HIV programs depend on.
Viral suppression matters because it is the difference between a patient who is stable and one who is not. When someone with HIV achieves suppression, their viral load becomes so low it is undetectable—and undetectable means untransmittable. But hepatitis B co-infection complicates everything. HBV can accelerate liver disease, raise the risk of cirrhosis and liver cancer, and make treatment management far more complex. A patient who is unsuppressed faces not just HIV-related risks but the added burden of progressive liver damage. The study, published in Tropical Medicine and Infectious Disease, raises a question that goes beyond statistics: Are Ethiopia's HIV programs equipped to care for patients who are managing more than one chronic infection at once?
The research points to adherence as the strongest predictor of suppression. Patients who took their medications consistently were far more likely to achieve viral control than those who missed doses. But adherence is not simply a matter of individual discipline. It is shaped by transport costs, stigma, side effects, work schedules, food insecurity, depression, clinic waiting times, and drug availability. For co-infected patients, the stakes are higher. A missed dose does not just risk HIV treatment failure—it can also undermine HBV control and accelerate liver damage. Yet adherence support in many settings remains generic counselling, not the targeted, intensive intervention that complex patients need.
Missed clinic appointments emerged as another critical signal. When patients skip visits, they miss viral load checks, regimen reviews, adherence support, and early detection of treatment failure. The study found that bedridden patients were particularly vulnerable—far less likely to achieve suppression than working patients. This points to a gap in how care is delivered. Standard clinic-based models assume patients can travel, wait, and return regularly. But patients with advanced disease, opportunistic infections, poor nutrition, or reduced mobility cannot always do that. They need care that reaches them where they are.
The study also identified a specific treatment regimen—TDF-3TC-LPV/r—that was associated with higher odds of suppression, along with longer time on antiretroviral therapy. This suggests that regimen choice and sustained treatment engagement matter. But the research has limits. It was cross-sectional, so it cannot prove cause and effect. Adherence was self-reported, which introduces bias. The study was limited to selected referral hospitals in Northwest Ethiopia, so its findings may not apply everywhere. And it lacked HBV-DNA and HBeAg data because these tests were not routinely available, limiting assessment of how active the hepatitis B infection was.
Despite those constraints, the study delivers a clear message to policymakers. Ethiopia needs stronger co-infection screening, better viral load and liver monitoring, patient-centered adherence services, appointment tracking systems, and differentiated care for high-risk patients. Development partners can support this through investment in laboratory capacity, digital follow-up tools, community-based retention models, and health-worker training. The wider lesson extends beyond Ethiopia: the next phase of HIV progress in the Global South will not be won by treatment availability alone. It will depend on whether health systems can deliver continuous, integrated, and responsive care to patients with complex needs—the patients who are hardest to reach and easiest to leave behind.
Notable Quotes
For co-infected patients, poor suppression can sit alongside HBV-related liver risks, making integrated care even more urgent— Study findings in Tropical Medicine and Infectious Disease
The next phase of HIV progress will not be won by treatment availability alone. It will depend on whether health systems can deliver continuous, integrated and responsive care to patients with complex needs— Study implications for the Global South
The Hearth Conversation Another angle on the story
Why does co-infection matter so much? Isn't viral suppression the same whether someone has hepatitis B or not?
Viral suppression is the goal, but co-infection changes what it takes to get there. Hepatitis B accelerates liver disease. A patient unsuppressed for HIV is also unsuppressed for HBV, so they're facing two infections at once. The treatment regimen has to manage both. Miss a dose and you're not just risking HIV failure—you're also letting HBV advance.
The study found that only one-third achieved suppression. That's a massive gap. What's actually stopping these patients?
It's not one thing. Adherence is the strongest predictor, but adherence depends on whether someone can afford transport to the clinic, whether they face stigma, whether they have food to eat, whether their work schedule allows time off. For bedridden patients, the barrier is even simpler: they can't get to the clinic at all.
So the problem isn't the drugs. It's the system.
Exactly. Ethiopia has the drugs. But the system isn't designed for patients with complex needs. Clinic appointments are missed because of distance or cost. Adherence support is generic. There's no tracking when someone stops coming. For co-infected patients, that's dangerous.
What would actually change this?
Integrated care. That means screening for both HIV and HBV together, monitoring liver function alongside viral load, offering adherence support that's targeted to each patient's barriers, tracking appointments before people disappear, and bringing care closer to people who can't travel. It also means choosing the right treatment regimen from the start—the study found that certain combinations work better.
Is this just an Ethiopia problem?
No. This is a Global South problem. Any country with overlapping HIV and HBV burdens faces this. The study is saying that treatment access alone isn't enough anymore. The real test is whether health systems can deliver care that's continuous, integrated, and responsive to people who are hardest to reach.